Cite
HARVARD Citation
Ladd, A. et al. (n.d.). A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma. Journal for immunotherapy of cancer. p. . [Online].